Skip to main content

Grafa News and Videos — Page 1557

Latest

Grafa
Technology

GoPro announces major restructuring plan including 23% global workforce reduction

GoPro (NASDAQ:GPRO) announced on April 7, 2026, that its Board of Directors has approved a comprehensive restructuring plan designed to significantly reduce operating costs and accelerate the company’s push toward stronger operating leverage.

Read more: GoPro announces major restructuring plan including 23% global workforce reduction
Grafa
Energy

SolarMax Technology reports record 296% revenue growth driven by massive BESS expansion

SolarMax Technology (NASDAQ:SMXT), a leading integrated solar energy company, announced record financial results for the fiscal year ended December 31, 2025, marked by a near-fourfold increase in revenue and a significant expansion of its energy storage pipeline.

Read more: SolarMax Technology reports record 296% revenue growth driven by massive BESS expansion
Grafa

Lexaria Bioscience welcomes FDA approval of Eli Lilly’s Foundayo as oral GLP-1 market expands

Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, issued a statement on April 7, 2026, applauding the U.S. Food and Drug Administration (FDA) approval of Eli Lilly’s Foundayo, the latest oral GLP-1 receptor agonist for chronic weight management in adults.

Read more: Lexaria Bioscience welcomes FDA approval of Eli Lilly’s Foundayo as oral GLP-1 market expands
Grafa
Technology

TransDigm finalizes $2.2B acquisition of Jet Parts Engineering and Victor Sierra Aviation

TransDigm Group (NYSE:TDG), a leading global designer, producer, and supplier of highly engineered aircraft components, announced on April 7, 2026, the successful completion of its acquisition of Jet Parts Engineering and Victor Sierra Aviation Holdings for approximately $2.2 billion in cash.

Read more: TransDigm finalizes $2.2B acquisition of Jet Parts Engineering and Victor Sierra Aviation
Grafa

Savara secures accelerated review in the UK for autoimmune PAP therapy MOLBREEVI

Savara (NASDAQ:SVRA), a clinical-stage biopharmaceutical company dedicated to rare respiratory diseases, announced on April 7, 2026, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its Marketing Authorisation Application (MAA) for MOLBREEVI.

Read more: Savara secures accelerated review in the UK for autoimmune PAP therapy MOLBREEVI

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift